The touch-screen device is about the size of notebook paper and weighs less than 9 pounds, including the battery. It also links to a mobile app, through which users can customize oscillation and other therapy settings to optimize the system for their particular needs. The device itself can store up to 20 different therapy profiles.
The BiWaze Cough System is important for patients with spinal cord injuries or neuromuscular deficits, according to the company. In these patients, suppressed ability to cough results in inability to clear respiratory tract secretions, which could block the airway and could result in pneumonia if aspirated.
“Receiving our first FDA 510(k) clearance is a great achievement for the company,” said Vinay Joshi, ABM CEO, in a statement. “We can now focus on executing our corporate strategy of integrating additional respiratory therapies into our BiWaze platform system and providing a truly novel approach to respiratory care.”
Product page: BiWaze Cough